3 ASX-listed healthcare stocks that are trending today – TLX, BDA, OSX


  • Oncology player Telix Pharmaceuticals has commenced Phase 3 clinical trial of its prostate cancer therapy candidate.
  • Polymer implants manufacturer Osteopore Limited has obtained CE certification for a significantly broader range of products.
  • Medicinal cannabis player Bod Australia has witnessed record medicinal cannabis sales during April.

Three Australian healthcare shares - Telix Pharmaceuticals Limited (ASX:TLX), Bod Australia Limited (ASX:BDA), and Osteopore Limited (ASX:OSX) - are trending on the ASX following major announcements.

Innovative regenerative implants manufacturer Osteopore revealed that it had obtained CE Mark while Telix Pharmaceuticals has commenced Phase 3 clinical trial of its prostate cancer therapy candidate. Medicinal cannabis company Bod Australia has hit record medicinal cannabis sales figures during April 2021.

Following the announcements, the three players witnessing a considerable movement in their share price. At 11:53 AM AEST, TLX, and BDA shares up 5.076% and 13.513% at AU$4.140 and AU$0.420. OSX shares were down 2.021% at AU$0.485.

The benchmark index, ASX 200 was up 1.08% (or 76.80 points) at AEST 11:54 AM). Some other ASX healthcare share faring well today morning include Paragon Care Limited (ASX:PGC) and Optiscan Imaging Limited (ASX:OIL).

DO READ: ASX 200 on Monday: Top 5 things to watch out

Let us now quickly discuss the updates of Telix, Bod and Osteopore:

Telix starts Phase 3 clinical trial

Telix Pharmaceuticals Limited disclosed that the Company had obtained clearance to commence a Phase 3 clinical trial of its prostate cancer therapy candidate, TLX591. TLX591 will be assessed in patients having advanced metastatic castrate-resistant prostate cancer.  Telix has obtained Research Ethics Committee (HREC) approval and received Clinical Trial Notification (CTN) clearance by the Therapeutic Goods Administration (TGA).

Source: Copyright © 2021 Kalkine Media Pty Ltd

The Phase 3 ProstACT trial is an international, multi-centre, randomised controlled trial in patients having PSMA-expressing mCRPC and will enrol ~390 patients.

The Company disclosed that it had initiated the study at the Australian ProstACT trial sites. The global sites for the trial will be added progressively during the second half of 2021, depending on the necessary approvals.

DID YOU KNOW: Telix (ASX:TLX) enters EU with Czech Republic’s TLX591-CDx authorisation

Bod Australia reported record monthly sales

Medicinal cannabis player Bod Australia Limited updated the market that the Company has recorded its highest ever month of medicinal cannabis sales during April. BDA filed a total of 1,789 MediCabilis™ new prescriptions in April in Australia.

This significant achievement takes total units sold in FY21 to 9,519, which marks a 138% increase in the sales during FY20.

Source: Copyright © 2021 Kalkine Media Pty Ltd

Furthermore, the Company is confident medicinal cannabis sales growth is anticipated to continue with the introduction of new products and the scale-up of UK operations.

BDA expects that the launch of new products and scale-up of operations across both business divisions will unlock significant shareholders value.

DO READ: Two Cannabis players expanding their product portfolio - AGH & BDA

Osteopore obtains CE mark

Osteopore Limited announced that it had obtained notification of the European MDD (Medical Devices Directive) certification for a significantly broader range of products. The Company disclosed that the CE Mark had been extended to include seven new shape variants and all sizes of Osteomesh, Osteoplug and Osteoplug-C.

Source: © Smile3377 | Megapixl.com

Osteopore also highlighted that more patients can now access the benefits of Osteopore’s technology with this expanded approval while undergoing cranial surgery.

Goh Khoon Seng, CEO of Osteopore, said that the MDD approval of the expanded product range was an exhilarating day for both the Company and the field of regenerative medicine.

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK